[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100409419":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":44,"centralContacts":48,"locations":58,"responsibleParty":74,"collaborators":77,"id":83,"slug":10,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":10,"eligibilityCriteria":87,"healthyVolunteers":84,"sex":88,"minAge":89,"maxAge":10,"enrollmentInfo":90,"targetDuration":10,"studyType":93,"phases":10,"briefSummary":94,"conditions":95,"keywords":10,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",[8,11,15,19,24],{"label":9,"type":10,"description":10,"interventionNames":10},"COVID survivors",null,{"label":12,"type":10,"description":10,"interventionNames":13},"Vaccination with CoronaVac vaccine",[14],"Biological: Vaccination with Coronavac vaccine",{"label":16,"type":10,"description":10,"interventionNames":17},"Vaccination with BionTech vaccine",[18],"Biological: Vaccination with BionTech Vaccine",{"label":20,"type":10,"description":21,"interventionNames":22},"third dose vaccination with CoronaVac vaccine","We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).",[23],"Biological: third dose vaccination with CoronaVac vaccine",{"label":25,"type":10,"description":21,"interventionNames":26},"third dose vaccination with BionTech vaccine",[27],"Biological: third dose vaccination with BionTech vaccine",[29,33,36,40],{"type":30,"name":20,"description":31,"armGroupLabels":32,"otherNames":10},"BIOLOGICAL","Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine",[20],{"type":30,"name":25,"description":34,"armGroupLabels":35,"otherNames":10},"Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine",[25],{"type":30,"name":37,"description":38,"armGroupLabels":39,"otherNames":10},"Vaccination with Coronavac vaccine","Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart",[12],{"type":30,"name":41,"description":42,"armGroupLabels":43,"otherNames":10},"Vaccination with BionTech Vaccine","Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart",[16],[45],{"name":46,"affiliation":5,"role":47},"David S Hui, MD","PRINCIPAL_INVESTIGATOR",[49,54],{"name":50,"role":51,"phone":52,"phoneExt":10,"email":53},"Susanna Ng, MBChB","CONTACT","85235053128","drsssng@gmail.com",{"name":55,"role":51,"phone":56,"phoneExt":10,"email":57},"Karen Yiu, BSc","85235053532","ysyiu@cuhk.edu.hk",[59],{"facility":60,"status":61,"city":62,"state":10,"zip":10,"country":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Prince of Wales Hospital","RECRUITING","Hong Kong",{"type":64,"coordinates":65},"Point",[66,67],114.17469,22.27832,{"lat":67,"lon":66},[70],{"name":71,"role":51,"phone":72,"phoneExt":10,"email":73},"Susanna So-Shan Ng","3505 2785","drsssng123@yahoo.com.hk",{"type":47,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Prof David Shu Cheong Hui","Professor",[78,80],{"name":79,"class":6},"The University of Hong Kong",{"name":81,"class":82},"Health and Medical Research Fund","OTHER_GOV","100409419",false,"NCT04611243","Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19","Inclusion Criteria: Patients who have been discharged from hospital following treatment for COVID-19 -\n\nExclusion Criteria: Unwilling to be follow up\n\n\\-","ALL","18 Years",{"count":91,"type":92},700,"ESTIMATED","OBSERVATIONAL","(a) Objectives\n\n1. To assess the full lung function, exercise capacity, quality of life in patients with COVID-19 over 2 years.\n2. To assess the longevity of the serology response to SARS-CoV2.\n3. To investigate the association of the neutralization titer in plasma from different vaccinated cohorts to its protection of infection using in vivo model\n4. To investigate the SARS-CoV-2 specific cellular and humoral immunities as well as their determinant factors from community subjects who have received different types of COVID-19 vaccines.\n5. To assess the third booster dose for subjects who have poor antibody response despite having received two doses of CoronaVac (Sinovac)",[96,97,98,99],"Lung Function","Exercise Capacity","Quality of Life","Covid19","2024-08-19",{"date":102,"type":103},"2024-08-21","ACTUAL",{"date":105,"type":103},"2020-05-22",{"date":107,"type":92},"2026-02-17",{"name":5,"class":6},1]